Skip to main content

Table 4 Value distribution of VEGF in various response groups of NSCLC patients during first-line chemotherapy

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

    

P

Biomarkers (unit)

Remission median (range)

No Change median (range)

Progression median (range)

R+NC vs P

R vs NC+P

VEGF BV1 (pg/mL)

364.0 (136.6-868.0)

180.5 (70.6-546.0)

286.4 (72.6-522.6)

0.589

0.083

VEGF BV2 (pg/mL)

144.0 (34.6-588.4)

237.8 (52.1-431.0)

325.2 (158.4-612.1)

0.001

0.016

VEGF BV3 (pg/mL)

119.0 (26.0-571.0)

269.7 (51.0-526.0)

402.8 (174.6-811.0)

0.001

0.001

VEGF BV1-2 (Dec%)

41.6 (2.2-86.8)

-6.6 (-90.6-64.5)

-18.5 (-118.2-2.7)

0.0001

0.0001

VEGF BV1-3 (Dec%)

63.0 (17.2-93.1)

-3.2 (-142.2-53.0)

-41.0 (-140.5- -17.8)

0.0001

0.0001

VEGF BV2-3 (Dec%)

12.7 (-62.4-87.1)

-21.2 (-33.6-33.8)

-15.3 (-66.3-5.3)

0.0268

0.0052

  1. BV1, BV2, and BV3, baseline VEGF levels before therapy cycle 1 to 3, respectively; BV1-2, BV1-3 and BV2-3, kinetics of baseline VEGF levels from cycles 1 to 2, 1 to 3 and 2 to 3, respectively; Dec%, decrease in percent (negative numbers meaning increase of the VEGF levels). P values by Wilcoxon test indicate differences between patients with progressive disease (P) and those having remission and stable disease (R+NC; evaluation 1) as well as between patients with remission (R) and those having progressive and stable disease (P+NC; evaluation 2).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us